In the United States, ARIKAYCE is the first and only FDA-approved therapy indicated for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug ...
BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Mycobacterium avium complex (MAC), a type of nontuberculous mycobacteria (NTM), lives all around us. You’ll find these germs in dirt, dust, and drinking water. They’re also common in natural sources ...
The MarketWatch News Department was not involved in the creation of this content. The MAC lung disease market is predicted to grow in the coming years. This growth is mainly driven by the launch of ...
On Thursday, AN2 Therapeutics, Inc. (NASDAQ:ANTX) released topline results from the Phase 2 part of the EBO-301 Phase 2/3 study of epetraborole on top of an optimized background regimen (OBR) in ...
If you have Mycobacterium avium complex (MAC) lung disease, your doctor may suggest treatment with Arikayce. It’s a prescription drug used together with other drugs to treat MAC lung disease that’s ...
Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese Patients Treatment-Refractory MAC Lung Disease Clinical Development ...
Dear Doctors: I suffered extensive fatigue that I had attributed to a COVID-19 infection. Then a lung culture found something called mycobacterium avium complex. Would you kindly consider discussing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback